Synergy of gatifloxacin with cefoperazone and cefoperazone–sulbactam against resistant strains of Pseudomonas aeruginosa

References

1. Bajaksouzian S., Visalli M. A., Jacobs M. R., Appelbaum P. C. 1996; Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time–kill methods. Antimicrob Agents Chemother 40:1973–1976
   [Google Scholar]
2. Dawis M. A., Isenberg H. D., France K. A., Jenkins S. G. 2003; In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 51:1203–1211 [CrossRef]
   [Google Scholar]
3. Eliopoulos G. M., Moellering R. C. Jr 1991; Laboratory methods used to assess the activity of antimicrobial combinations. In Antibiotics in Laboratory Medicine , 3rd edn. pp 432–492 Edited by Lorian V. Baltimore, MD: Williams & Wilkins;
   [Google Scholar]
4. Fish D. N., Choi M. K., Jung R. 2002; Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 50:1045–1049 [CrossRef]
   [Google Scholar]
5. Gradelski E., Valera L., Bonner D., Fung-Tomc J. 2001; Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Antimicrob Agents Chemother 45:3220–3222 [CrossRef]
   [Google Scholar]
6. Mayer I., Nagy E. 1999; Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 43:651–657 [CrossRef]
   [Google Scholar]
7. CLSI 1999 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically , 5th edn. approved standard M7–A5 Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
8. CLSI 2000 Performance Standards for Antimicrobial Disk Susceptibility Test , approved standard M7–A5 Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
9. Neu H. C., Chin N. X. 1994; In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 38:2615–2622 [CrossRef]
   [Google Scholar]
10. Pankey G. A., Ashcraft D. S. 2005; In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa . Antimicrob Agents Chemother 49:2959–2964 [CrossRef]
    [Google Scholar]
11. PDR 2004 Physicians' Desk Reference , 58th edn. Montvale, NJ: Thomsons;
    [Google Scholar]
12. Rossolini G. M., Mantengoli E. 2005; Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa . Clin Microbiol Infect 11 (Suppl. 4):17–32
    [Google Scholar]
13. Visalli M. A., Jacobs M. R., Appelbaum P. C. 1998; Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time–kill methodology. Antimicrob Agents Chemother 42:953–955
    [Google Scholar]